122 related articles for article (PubMed ID: 34846570)
1. Efficacy of dexamethasone in the management of malignant small bowel obstruction in advanced epithelial ovarian cancer.
Jones APM; McGauran MFG; Jagasia N; Hiscock RJ; Hyde S; Grant P
Support Care Cancer; 2022 Mar; 30(3):2821-2827. PubMed ID: 34846570
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC).
Kolomainen DF; Daponte A; Barton DP; Pennert K; Ind TE; Bridges JE; Shepherd JH; Gore ME; Kaye SB; Riley J
Gynecol Oncol; 2012 Apr; 125(1):31-6. PubMed ID: 22082991
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
6. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
[TBL] [Abstract][Full Text] [Related]
8. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
9. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction.
Chouhan J; Gupta R; Ensor J; Raghav K; Fogelman D; Wolff RA; Fisch M; Overman MJ
Cancer Med; 2016 Feb; 5(2):239-47. PubMed ID: 26714799
[TBL] [Abstract][Full Text] [Related]
13. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
14. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Eichbaum M; Mayer C; Eickhoff R; Bischofs E; Gebauer G; Fehm T; Lenz F; Fricke HC; Solomayer E; Fersis N; Schmidt M; Wallwiener M; Schneeweiss A; Sohn C
BMC Cancer; 2011 Oct; 11():453. PubMed ID: 22014006
[TBL] [Abstract][Full Text] [Related]
15. A single-centre ten-year retrospective cohort study of malignant small bowel obstruction.
Cato LD; Evans T; Ward ST
Ann R Coll Surg Engl; 2021 Nov; 103(10):738-744. PubMed ID: 34436951
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
[TBL] [Abstract][Full Text] [Related]
17. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer.
Quan Q; Zhou S; Liu Y; Yin W; Liao Q; Ren S; Zhang F; Meng Y; Mu X
J Obstet Gynaecol Res; 2021 Apr; 47(4):1527-1535. PubMed ID: 33506580
[TBL] [Abstract][Full Text] [Related]
18. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
Webber K; Friedlander M
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():126-138. PubMed ID: 28027849
[TBL] [Abstract][Full Text] [Related]
20. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]